Indalo’s lead drug candidate, IDL-2965, is an oral, selective antagonist of RGD-binding integrins avb1, avb3, and avb6 that uniquely inhibits multiple processes of pathologic fibrosis, including the local activation of TGF-b by both epithelial cells and fibroblasts, as well as the ability of stiff extracellular matrix to promote fibroblast migration and survival.
IDL-2965 recently demonstrated excellent safety, tolerability, and oral pharmacokinetics in healthy volunteers. Dosing has initiated in a proof-of-biology study in IPF patients in preparation for the initiation of late-stage pivotal trials. Studies in NASH patient are planned for 2020.
In preclinical models, IDL-2965 provides potent antifibrotic efficacy at low once-daily oral doses across multiple animal models of disease in vital organ systems, including lung, liver, and kidney.
Rat liver fibrosis from CCl4 with and without treatment with IDL-2965.